# A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

> **NCT03449030** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

## Interventions

- **DRUG:** TAK-164
- **DRUG:** 89Zr-TAK-164

## Key facts

- **NCT ID:** NCT03449030
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-23
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Insufficient clinical benefit to participants at the selected recommended phase 2 (RP2D) dose in Part A.
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449030, "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03449030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*